GleamWall
中文EN

STTK Shattuck Labs, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680367 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-66.6%
TTM net income YoY14.5%
TTM EPS YoY63.6%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,578.7%
Net margin-5,256.8%
FCF margin—
EBITDA margin-5,221.0%

Returns

ROE-39.2%
ROA-36.9%
ROIC (approx.)-57.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets4.3%
Debt / equity0.00x
Current ratio27.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$1.00M$0$0$0
R&D expense$21.57M$11.70M$10.95M$9.05M$7.62M$8.68M$9.92M$15.39M
SG&A expense$5.48M$4.46M$4.60M$4.32M$4.10M$4.35M$4.47M$4.25M
Operating income-$27.05M-$16.16M-$15.54M-$13.37M-$10.72M-$13.03M-$14.39M-$19.64M
Net income-$25.20M-$15.15M-$14.77M-$12.59M-$10.06M-$12.46M-$13.70M-$18.68M
EBITDA-$26.23M-$15.30M-$14.65M-$12.45M-$9.80M-$12.10M-$13.45M-$18.73M
EPS (basic)-0.14-0.12-0.13—-0.14-0.24-0.27—
EPS (diluted)-0.14-0.12-0.13—-0.14-0.24-0.27—
Weighted avg. shares (diluted)183.22B129.78M112.23M—72.18B51.00M50.97M—
Balance sheet
Cash & equivalents$61.76M$63.30M$90.42M$54.19M$42.55M$50.47M$60.90M$57.39M
Current assets$201.60M$213.27M$93.75M$82.47M$90.72M$54.67M$66.40M$79.22M
PP&E, net$3.63M$4.51M$5.35M$6.11M$7.05M$7.95M$8.88M$9.81M
Total assets$207.97M$220.67M$102.12M$91.03M$100.33M$64.37M$77.17M$91.05M
Current liabilities$12.76M$7.73M$4.25M$7.05M$5.34M$5.34M$7.32M$8.92M
Total liabilities$14.31M$9.53M$6.29M$8.64M$7.09M$7.35M$9.58M$11.42M
Shareholders' equity$193.66M$211.14M$95.83M$82.39M$93.24M$57.02M$67.59M$79.63M
Shares outstanding101.83M100.73M75.58M63.28M63.15M47.90M47.90M47.71M
Cash flow statement
Operating cash flow-$17.47M-$10.19M-$13.42M-$8.49M-$8.93M-$10.43M-$12.03M-$17.37M
Capital expenditure$50,000——$0$71,000——$0
Free cash flow-$17.52M——-$8.49M-$9.00M——-$17.37M
Investing cash flow$11.73M-$144.95M$23.85M$20.00M-$43.49M$0$15.60M$31.00M
Financing cash flow$4.20M$128.01M$25.80M$134,000$44.50M$0-$57,000-$72,000
Depreciation & amortization$813,000$851,000$891,000$918,000$917,000$929,000$936,000$911,000
Stock-based compensation$3.30M$2.73M$2.42M$1.61M$1.78M$1.89M$1.72M$1.85M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.